Patient and disease characteristics and length of follow-up in donor versus no donor trials
| Trial . | Ph+ excluded . | Total analyzed . | Sex . | Age, y . | WBC . | Immunophenotype . | Median follow-up, y . | Lost to follow-up < 5 y . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M . | F . | < 25 . | 25-34 . | 35-44 . | ≥ 45 . | < 30 . | 30-99 . | > 100 . | B . | T . | Other . | |||||
| MRC UKALLXA21 | 22 | 134 | 92 (69%) | 42 (31%) | 75 (56%) | 35 (6%) | 18 (13%) | 6 (4%) | 28 (21%) | 46 (34%) | 60 (45%) | 57 (50%) | 53 (47%) | 3 (3%) | 16.4 | 1 (1%) |
| PMH 9223 | 17 | 70 | 50 (71%) | 20 (29%) | 28 (40%) | 17 (24%) | 19 (27%) | 6 (9%) | 46 (70%) | 14 (21%) | 6 (9%) | 44 (65%) | 24 (35%) | 0 (0%) | 8.4 | 3 (4%) |
| JALSG-ALL9324 | 14 | 129 | 74 (7%) | 55 (43%) | 78 (60%) | 30 (23%) | 20 (16%) | 1 (1%) | 94 (73%) | 22 (7%) | 13 (10%) | 92 (74%) | 15 (12%) | 17 (14%) | 4.7 | 33 (26%) |
| GRAALL 200325 | 0 | 132 | 87 (66%) | 45 (34%) | 55 (42%) | 27 (20%) | 27 (20%) | 23 (17%) | 76 (58%) | 30 (23%) | 25 (19%) | 90 (68%) | 42 (32%) | 0 (0%) | 4.0 | 77 (58%) |
| HOVON 18 ALL27 | 10 | 94 | 55 (59%) | 39 (41%) | 48 (51%) | 21 (22%) | 15 (16%) | 10 (11%) | 66 (70%) | 14 (15%) | 14 (15%) | 65 (69%) | 27 (29%) | 2 (2%) | 9.5 | 1 (1%) |
| GOELAL0228 | 18 | 128 | 86 (67%) | 42 (33%) | 56 (44%) | 37 (29%) | 24 (19%) | 11 (9%) | 77 (60%) | 35 (27%) | 16 (13%) | 94 (73%) | 34 (27%) | 0 (0%) | 4.7 | 38 (30%) |
| HILG ALL08/9629 | 18 | 45 | 13 (29%) | 32 (71%) | 10 (22%) | 17 (38%) | 10 (22%) | 8 (18%) | 28 (62%) | 17 (38%) | 0 (0%) | 9.9 | 1 (2%) | |||
| HOVON 37 ALL27 | 30 | 160 | 99 (62%) | 61 (38%) | 59 (37%) | 39 (24%) | 31 (19%) | 31 (19%) | 122 (76%) | 19 (12%) | 19 (12%) | 112 (70%) | 45 (28%) | 3 (2%) | 5.4 | 33 (21%) |
| EORTC 0686111 | 11 | 220 | 148 (67%) | 72 (33%) | 101 (46%) | 54 (25%) | 45 (20%) | 20 (9%) | 141 (65%) | 43 (20%) | 34 (16%) | 113 (62%) | 51 (28%) | 19 (10%) | 10.9 | 8 (4%) |
| UKALLXII/E299314 | 154 | 1193 | 765 (64%) | 428 (36%) | 520 (44%) | 318 (27%) | 232 (19%) | 123 (10%) | 793 (67%) | 214 (18%) | 181 (15%) | 872 (75%) | 280 (24%) | 15 (1%) | 8.2 | 135 (11%) |
| PETHEMA ALL-9315 | 26 | 154 | 86 (56%) | 68 (44%) | 71 (46%) | 46 (30%) | 29 (19%) | 8 (5%) | 82 (53%) | 43 (28%) | 29 (19%) | 99 (64%) | 55 (36%) | 0 (0%) | 6.3 | 25 (16%) |
| LALA-9416 | 104 | 290 | 179 (62%) | 111 (38%) | 96 (33%) | 63 (22%) | 60 (21%) | 71 (24%) | 170 (59%) | 64 (22%) | 56 (19%) | 205 (81%) | 46 (18%) | 1 (0%) | 6.4 | 33 (11%) |
| EORTC ALL-4/0695117 | 18 | 213 | 120 (56%) | 93 (44%) | 85 (40%) | 48 (23%) | 44 (21%) | 36 (17%) | 147 (69%) | 39 (18%) | 27 (13%) | 134 (63%) | 69 (32%) | 10 (5%) | 6.5 | 23 (11%) |
| Trial . | Ph+ excluded . | Total analyzed . | Sex . | Age, y . | WBC . | Immunophenotype . | Median follow-up, y . | Lost to follow-up < 5 y . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M . | F . | < 25 . | 25-34 . | 35-44 . | ≥ 45 . | < 30 . | 30-99 . | > 100 . | B . | T . | Other . | |||||
| MRC UKALLXA21 | 22 | 134 | 92 (69%) | 42 (31%) | 75 (56%) | 35 (6%) | 18 (13%) | 6 (4%) | 28 (21%) | 46 (34%) | 60 (45%) | 57 (50%) | 53 (47%) | 3 (3%) | 16.4 | 1 (1%) |
| PMH 9223 | 17 | 70 | 50 (71%) | 20 (29%) | 28 (40%) | 17 (24%) | 19 (27%) | 6 (9%) | 46 (70%) | 14 (21%) | 6 (9%) | 44 (65%) | 24 (35%) | 0 (0%) | 8.4 | 3 (4%) |
| JALSG-ALL9324 | 14 | 129 | 74 (7%) | 55 (43%) | 78 (60%) | 30 (23%) | 20 (16%) | 1 (1%) | 94 (73%) | 22 (7%) | 13 (10%) | 92 (74%) | 15 (12%) | 17 (14%) | 4.7 | 33 (26%) |
| GRAALL 200325 | 0 | 132 | 87 (66%) | 45 (34%) | 55 (42%) | 27 (20%) | 27 (20%) | 23 (17%) | 76 (58%) | 30 (23%) | 25 (19%) | 90 (68%) | 42 (32%) | 0 (0%) | 4.0 | 77 (58%) |
| HOVON 18 ALL27 | 10 | 94 | 55 (59%) | 39 (41%) | 48 (51%) | 21 (22%) | 15 (16%) | 10 (11%) | 66 (70%) | 14 (15%) | 14 (15%) | 65 (69%) | 27 (29%) | 2 (2%) | 9.5 | 1 (1%) |
| GOELAL0228 | 18 | 128 | 86 (67%) | 42 (33%) | 56 (44%) | 37 (29%) | 24 (19%) | 11 (9%) | 77 (60%) | 35 (27%) | 16 (13%) | 94 (73%) | 34 (27%) | 0 (0%) | 4.7 | 38 (30%) |
| HILG ALL08/9629 | 18 | 45 | 13 (29%) | 32 (71%) | 10 (22%) | 17 (38%) | 10 (22%) | 8 (18%) | 28 (62%) | 17 (38%) | 0 (0%) | 9.9 | 1 (2%) | |||
| HOVON 37 ALL27 | 30 | 160 | 99 (62%) | 61 (38%) | 59 (37%) | 39 (24%) | 31 (19%) | 31 (19%) | 122 (76%) | 19 (12%) | 19 (12%) | 112 (70%) | 45 (28%) | 3 (2%) | 5.4 | 33 (21%) |
| EORTC 0686111 | 11 | 220 | 148 (67%) | 72 (33%) | 101 (46%) | 54 (25%) | 45 (20%) | 20 (9%) | 141 (65%) | 43 (20%) | 34 (16%) | 113 (62%) | 51 (28%) | 19 (10%) | 10.9 | 8 (4%) |
| UKALLXII/E299314 | 154 | 1193 | 765 (64%) | 428 (36%) | 520 (44%) | 318 (27%) | 232 (19%) | 123 (10%) | 793 (67%) | 214 (18%) | 181 (15%) | 872 (75%) | 280 (24%) | 15 (1%) | 8.2 | 135 (11%) |
| PETHEMA ALL-9315 | 26 | 154 | 86 (56%) | 68 (44%) | 71 (46%) | 46 (30%) | 29 (19%) | 8 (5%) | 82 (53%) | 43 (28%) | 29 (19%) | 99 (64%) | 55 (36%) | 0 (0%) | 6.3 | 25 (16%) |
| LALA-9416 | 104 | 290 | 179 (62%) | 111 (38%) | 96 (33%) | 63 (22%) | 60 (21%) | 71 (24%) | 170 (59%) | 64 (22%) | 56 (19%) | 205 (81%) | 46 (18%) | 1 (0%) | 6.4 | 33 (11%) |
| EORTC ALL-4/0695117 | 18 | 213 | 120 (56%) | 93 (44%) | 85 (40%) | 48 (23%) | 44 (21%) | 36 (17%) | 147 (69%) | 39 (18%) | 27 (13%) | 134 (63%) | 69 (32%) | 10 (5%) | 6.5 | 23 (11%) |